Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (6983)	8/25/1998 5:45:00 PM
From: Tharos	Respond to of 17367

I would temper that statement a bit: If you know why you bought a company. If the reasons you previously bought a company are still valid. Then cost averaging through regular purchases is an excellent way to reduce risk. With that qualifier in mind: I concur, I have been "cost averaging" at these prices.

To: Bluegreen who wrote (6983)	8/25/1998 6:52:00 PM
From: aknahow	Respond to of 17367

I would like to se the trials halted. Think this would depend on XOMA believing it was worth changing its' original agreement with the FDA to run the trials through Dec and evaluate the results on whatever number of patients that had been accumulated at that time. Since the accruals are much higher than originally anticipated it is possible that XOMA might seek to do this. BUT--- I think it is prudent to remember that XOMA has so far said they intend to continue the trials thru the original time frame, agreed to with the FDA. BTW comparison of cost of treatment vs vaccine in Africa. Use data with care as the programs were run in Africa and vaccines were used only after outbreaks had already occurred. Effectiveness of treatment vs vaccine were about the same. Big cost difference in favor of treatment, but as explained in article this difference may not mean much. ncbi.nlm.nih.gov